COMPANY

Genprex

HQ: Austin, TX source · genprex.com ↗ · Southwest

Our technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. From company website Source · Oct 13, 2026

Keywords: oncology metabolic cancer diabetes mellitus nanoparticles gene therapy AAV Non-Small Cell Lung Carcinoma Small Cell Lung Cancer Extensive Stage Non Small Cell Lung Cancer Lung Cancer

Location: Austin, TX · source · Oct 14, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Raises and deals from press releases

Deal Roche deal · amount not disclosed · announced Aug 3, 2026 Company release ↗
Source quote
- Aug 3, 2026 · Company release ↗
  “Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies”

From the company’s own releases; this list is partial. All raises and deals

Timeline

May 9, 2024 Trial start Phase 1/Phase 2: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients source ↗
Mar 30, 2022 Trial start Phase 1: Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer source ↗
Sep 3, 2021 Trial start Phase 1/Phase 2: Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib source ↗
2014-02 Trial start Phase 1/Phase 2: TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer source ↗

Upcoming milestones

2027-12 (ESTIMATED) · Phase 1/Phase 2 · Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients · NCT05703971
2028-03 (ESTIMATED) · Phase 1/Phase 2 · Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib · NCT04486833

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT04486833	Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib	Phase 1/Phase 2	Recruiting	Sep 3, 2021	2028-03 (estimated)
NCT05703971	Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients	Phase 1/Phase 2	Recruiting	May 9, 2024	2027-12 (estimated)
NCT05062980	Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer	Phase 1	Terminated	Mar 30, 2022	Feb 3, 2025 (actual)
NCT01455389	TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer	Phase 1/Phase 2	Terminated	2014-02	Oct 27, 2016 (actual)